Talimogene laherparepvec clinical trials
Also written Imlygic, JS1 34.5-hGMCSF 47- pA- and ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene.
How each study uses talimogene laherparepvec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the talimogene laherparepvec studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Oct 2015 · Imlygic · BLA 125518 (FDA, Purple Book)
- European Union
- 16 Dec 2015 · Imlygic · EMEA/H/C/002771 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2019 (8)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 5 |
| 2019 | 8 |
| 2020 | 5 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 26
Amgen (11) · BioVex Limited (6) · National Cancer Institute (NCI) (4) · John Rieth (2) · Memorial Sloan Kettering Cancer Center (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · SOLTI Breast Cancer Research Group (1) · The Netherlands Cancer Institute (1)
Often tested with
Tested in the same studies.
Pembrolizumab (5) · Nivolumab (4) · Atezolizumab (2) · Panitumumab (1) · Ipilimumab (1) · Trametinib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test talimogene laherparepvec.
- Dec 2026Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Phase 1 · Johns Hopkins University
- Dec 2026Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by SurgeryPhase 2 · National Cancer Institute (NCI)
- Sep 2027Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersPhase 2 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses talimogene laherparepvec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 43
- Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1RecruitingPhase 1Johns Hopkins UniversityNCT07102394Written as ImlygicHow we know
- Neoadjuvant Combination Immunotherapy for Stage III MelanomaRecruitingPhase 2University of LouisvilleNCT03842943Written as Talimogene LaherparepvecHow we know
- Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02978625Written as Talimogene LaherparepvecHow we know
- Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by SurgeryActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02923778Written as Talimogene LaherparepvecHow we know
- Neoadjuvant Intralesional Injection of Talimogene LaherparepvecActive, not recruitingPhase 2John RiethNCT06660810Written as Talimogene LaherparepvecHow we know
- A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03069378Written as Talimogene Laherparepvec (T-VEC)How we know
- Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02965716Written as Talimogene LaherparepvecHow we know
- Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast CancerCompletedPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT02779855Written as Talimogene laherparepvecHow we know
- TVEC and Preop Radiation for Sarcoma (8 ml Dose)Active, not recruitingPhase 1/2John RiethNCT04599062Written as Talimogene LaherparepvecHow we know
- Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the SkinTerminatedPhase 1Rutgers, The State University of New JerseyNCT04163952Written as Talimogene LaherparepvecHow we know
- Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerCompletedEarly Phase 1SOLTI Breast Cancer Research GroupNCT03802604Written as Talimogene laherparepvecHow we know
- Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable DiseaseCompletedPhase 2The Netherlands Cancer InstituteNCT04330430Written as T-VECHow we know
- A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT02819843Written as TALIMOGENE LAHERPAREPVEC (TVEC)How we know
- Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).CompletedPhase 2AmgenNCT04068181Written as Talimogene laherparepvecHow we know
- Study of Talimogene Laherparepvec (T-VEC) in Pancreatic CancerCompletedPhase 1Karie D. Runcie, MDNCT03086642Written as Talimogene laherparepvecHow we know
- Talimogene Laherparepvec for the Treatment of Peritoneal Surface MalignanciesCompletedPhase 1Dan Blazer III, M.D.NCT03663712Written as Talimogene LaherparepvecHow we know
- Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611CompletedPhase 1/2AmgenNCT02509507Written as Talimogene LaherparepvecHow we know
- TVEC and Preop Radiation for Sarcoma (4 ml Dose)CompletedPhase 1/2University of IowaNCT02453191Written as Talimogene LaherparepvecHow we know
- Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal CancerTerminatedPhase 1National Cancer Institute (NCI)NCT03300544Written as Talimogene LaherparepvecHow we know
- Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesCompletedPhase 1AmgenNCT03256344Written as Talimogene LaherparepvecHow we know
See all 43 studies that test talimogene laherparepvec →
Given beside what is tested · 3 — talimogene laherparepvec is usual care or a partner of the new treatment
- Talimogene Laherparepvec, Nivolumab and Trabectedin for SarcomaRecruitingPhase 2Sarcoma Oncology Research Center, LLCNCT03886311Written as Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]How we know
- T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerCompletedPhase 1University of California, San FranciscoNCT03554044Written as Talimogene LaherparepvecHow we know
- Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced MelanomaStatus unknownPhase 1West Cancer CenterNCT03088176Written as Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,VilHow we know
Codes
What other systems call talimogene laherparepvec · ClinicalTrials.gg INT001044
- MeSH (NLM) C000629782talimogene laherparepvecConfirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) 07730V90L6TALIMOGENE LAHERPAREPVECConfirmed FDA, Wikidata
- RxNorm 1721264Confirmed FDA, Wikidata
- Wikidata Q7679524talimogene laherparepvecConfirmed FDA, Wikidata
- NCI Thesaurus C61314Talimogene LaherparepvecOne source FDA
- DrugBank DB13896One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629782 | talimogene laherparepvec | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | 07730V90L6 | TALIMOGENE LAHERPAREPVEC | Confirmed FDA, Wikidata |
| RxNorm | 1721264 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7679524 | talimogene laherparepvec | Confirmed FDA, Wikidata |
| NCI Thesaurus | C61314 | Talimogene Laherparepvec | One source FDA |
| DrugBank | DB13896 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.